



July 28, 2011

Corporate Facts

& Figures

Cytos Biotechnology at a Glance

- Cytos Biotechnology is a Swiss public biotechnology company that focuses on the discovery, development and commercialization of a new class of biopharmaceutical products – the Immunodrugs™.
- Immunodrugs™ are therapeutic vaccines intended for use in the treatment and prevention of common chronic diseases that afflict millions of people worldwide.
- Founded in 1995, Cytos Biotechnology currently has 73 full-time equivalents and is headquartered in Schlieren (Zurich), Switzerland.
- Cytos Biotechnology Ltd is listed on the main segment at the SIX Swiss Exchange:
 - registered shares – SIX:CYTN
 - convertible bond due in 2012 – SIX:CYT07

Recent News

- June 2011 – Update on combined phase I/IIa study with a novel anti-interleukin-1 beta vaccine in patients with type II diabetes mellitus.
- June 2011 – Phase IIb results with CYT003-QbG10 for the treatment of allergic rhinoconjunctivitis published in the Journal “Clinical and Experimental Allergy”.
- March 2011 – United States Army and Cytos Biotechnology collaborate on malaria vaccines research.
- February 2011 – Cytos Biotechnology receives EU funding to work on novel vaccine approaches for emerging viral diseases.
- February 2011 – Cytos Biotechnology presented latest data on the mechanism of action of QbG10 for the treatment of allergic asthma at the 3rd International Conference on Drug Discovery and Therapy.

Business Strategy

- Chronic disease treatment and prevention requires early intervention and long-term patient compliance to respective therapies if individual well-being is to be maintained. Cytos Biotechnology’s Immunodrugs™ represent a new therapeutic modality that aims to offer therapeutic benefit and convenient dosing schedules to individual patients as well as economic benefit to payers of treatment and society in general.
- Cytos Biotechnology generally selects disease indications with well understood disease mechanisms and therapeutic pathways where Immunodrugs™ should provide for an attractive treatment solution.
- To maximize the commercial potential of its Immunodrug™ platform, Cytos Biotechnology intends to follow different avenues:
 - selectively partner Immunodrug™ projects addressing mass markets after clinical proof-of-concept (e.g. in phase II trials) with leading pharmaceutical companies;
 - provide pharmaceutical companies with access to the Immunodrug™ technology in well defined, target-specific licensing arrangements outside the scope of Cytos Biotechnology’s own R&D programs; and,
 - benefit from potential cross-sector opportunities by applying Immunodrugs™ in human and animal health.

Product Pipeline (July 2011)

		Preclinical	Phase I	Phase II	Phase IIb
Respiratory	CYT003-QbG10 for allergic rhinoconjunctivitis				
	CYT003-QbG10 for allergic asthma				
	VLP-IgE vaccine for allergic diseases	partnered with Pfizer			
	NIC002 for smoking cessation	partnered with Novartis			
Cardiovascular	CYT006-AngQb for hypertension				
Nervous system	CAD106 for Alzheimer's disease	partnered with Novartis			
Metabolic	CYT013-IL1bQb for type II diabetes				
Inflammation/ Autoimmunity	CYT020-TNFQb for inflammation				
	CYT017-IL17Qb for multiple sclerosis/psoriasis				
Infectious diseases	Influenza Vaccine Qb-Flu	partnered with Singapore			
	Malaria Vaccine	collaboration with NIH			

Product Pipeline

Cytos Biotechnology has built a diversified pipeline of Immunodrug™ candidates targeting important chronic disease indications. Five product candidates for smoking cessation, allergy and asthma, Alzheimer's disease, hypertension and type II diabetes are currently in clinical development. The Immunodrug™ programs for smoking cessation and Alzheimer's disease are both partnered with Novartis. In addition, Immunodrug™ collaborations are ongoing with Pfizer in undisclosed human and animal health applications.

Partnerships

- Cytos Biotechnology's innovative technologies and product candidates are partnered with top-tier pharmaceutical companies. The main partners are Novartis, Pfizer, Pfizer Animal Health and Solidago.
- A worldwide scientific network with prestigious academic research institutions gives Cytos Biotechnology prime access to cutting-edge science, disease-specific know-how and additional specimens and research materials.

Contact

Cytos Biotechnology Ltd
 Wagistrasse 25
 CH-8952 Schlieren (Zurich)
 Switzerland
 Phone +41 44 733 47 47
 Fax +41 44 733 47 40
 info@cytos.com
 www.cytos.com

Financial Overview

in CHF million	Q2 2011	full year 2010
Revenue	0.4	22.3
Net operating costs	(4.7)	(26.2)
Net loss	(4.7)	(1.5)

in CHF million	June 30, 2011	December 31, 2010
Cash, cash equivalents, financial assets and trade and other receivables	37.5	48.7
Convertible bonds (outstanding nominal value)	41.1	41.1
Number of full-time equivalents	73	81

The full financial statements can be found on www.cytos.com

Disclaimer: This fact sheet has the sole purpose to provide, in a simplified way, an overview of Cytos Biotechnology and its activities. Cytos Biotechnology can offer neither assurance that this overview is complete nor that its technology and product candidates will be successful. This fact sheet does not constitute or form part of an offer to subscribe or purchase any securities of Cytos Biotechnology Ltd. Any person considering the purchase of or subscription to securities in Cytos Biotechnology Ltd shall inform himself independently from other sources before taking any investment decision. Forward-looking statements represent the judgment and expectation of Cytos Biotechnology's management concerning the development of Cytos Biotechnology. However, a number of risks and uncertainties could cause actual developments and results to differ materially from Cytos Biotechnology's expectation.